Elina Teicher, Chadi Abbara, Jean‐Charles Duclos‐Vallée, Teresa Antonini, Laurence Bonhomme‐Faivre, Delphine Desbois, Didier Samuel, Daniel Vittecoq – 29 September 2009 – The aim of this study was to evaluate the impact of an enfuvirtide‐based antiretroviral (ARV) regimen on the management of immunosuppression and follow‐up in hepatitis C virus (HCV)/hepatitis B virus (HBV)/human immunodeficiency virus (HIV)–coinfected liver transplant patients in comparison with a lopinavir/ritonavir‐based ARV regimen.

Michael Leise, W. Ray Kim – 29 September 2009

Sadahisa Okamoto, Jonas Wixner, Konen Obayashi, Yukio Ando, Bo‐Göran Ericzon, Styrbjörn Friman, Makoto Uchino, Ole B. Suhr – 29 September 2009 – Liver transplantation (LTx) for familial amyloidotic polyneuropathy (FAP) is an accepted treatment for this fatal disease. However, the long‐term outcome with respect to that of nontransplanted patients has not been fully elucidated. The aim of this study was to compare the long‐term survival of Swedish LTx FAP patients with that of historical controls, especially with respect to the age at onset of the disease and gender.

Christopher Vinnard, Todd Barton, Elliot Jerud, Emily Blumberg – 29 September 2009 – Human herpesvirus 6 (HHV‐6) is a common pathogen among children, classically presenting as fever and rash that resolve without specific therapy (exanthem subitum or roseola infantum). Also identified as a pathogen in hematopoietic cell transplant and solid organ transplant (SOT) recipients, it has been recognized as a cause of limbic encephalitis, characterized by confusion and amnesia, with magnetic resonance imaging findings of T2 hyperintensity of the amygdala and hippocampus.

Martín Prieto – 29 September 2009

Kai Kang, Mingyan Zhao, Hongchi Jiang, Gang Tan, Shangha Pan, Xueying Sun – 29 September 2009 – Hydrogen sulfide (H2S) displays anti‐inflammatory and cytoprotective activities as evidenced by the inhibition of myocardial ischemia‐reperfusion injury and production of lipid peroxidation. H2S also exerts many physiological or pathological effects on livers.

Sumihito Tamura, Yasuhiko Sugawara, Noriyo Yamashiki, Junichi Kaneko, Norihiro Kokudo – 29 September 2009

Lei Yu, Thomas Koepsell, Lisa Manhart, George Ioannou – 29 September 2009 – Liver transplantation using grafts from donors with antibody against hepatitis B core antigen (anti‐HBc) increases the recipients' risk of developing hepatitis B virus (HBV) infection post‐transplantation. Our aim was to assess whether using such grafts was associated with reduced posttransplantation survival and whether this association depended on recipients' prior exposure to HBV on the basis of their pretransplantation serological patterns.

Luis Olmedilla, José María Pérez‐Peña, Cristina Ripoll, Ignacio Garutti, Roberto de Diego, Magdalena Salcedo, Consuelo Jiménez, Rafael Bañares – 29 September 2009 – Early diagnosis of graft dysfunction in liver transplantation is essential for taking appropriate action. Indocyanine green clearance is closely related to liver function and can be measured noninvasively by spectrophotometry.

Paolo De Simone, Herold J. Metselaar, Lutz Fischer, Jérôme Dumortier, Karim Boudjema, Jean Hardwigsen, Lionel Rostaing, Luciano De Carlis, Faouzi Saliba, Frederik Nevens – 29 September 2009 – Calcineurin inhibitors (CNIs) contribute to renal dysfunction following liver transplantation. This prospective, randomized, multicenter, 6‐month study (with an additional 6 months of follow‐up) evaluated whether everolimus with CNI reduction or discontinuation would improve renal function in maintenance liver transplant recipients experiencing CNI‐related renal impairment.